Compare NOAH & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | AURA |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 713.4M |
| IPO Year | 2010 | 2021 |
| Metric | NOAH | AURA |
|---|---|---|
| Price | $8.45 | $7.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.00 | ★ $20.00 |
| AVG Volume (30 Days) | 86.8K | ★ 491.8K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.40 | $4.73 |
| 52 Week High | $12.84 | $9.54 |
| Indicator | NOAH | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 25.71 | 49.52 |
| Support Level | N/A | $6.61 |
| Resistance Level | $10.73 | $7.04 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 1.47 | 46.67 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.